A T cell–engaging bispecific antibody immunotherapy that binds Claudin 18.2 on tumor cells and CD3 on T cells to redirect and activate endogenous T cells, inducing cytotoxic killing of tumor cells; administered intravenously or subcutaneously.
Affinity-optimized bispecific antibody that binds CLDN18.2 on tumor cells (bivalent, high affinity) and CD3 on T cells (monovalent, low affinity), crosslinking tumor cells and T cells to activate and expand cytotoxic T lymphocytes, triggering TCR signaling, immune synapse formation, cytokine release, and lysis of CLDN18.2-positive tumor cells with potential bystander killing.
NO
INDIRECT
AZD5863 binds CD3 on T cells to activate and redirect them to kill CLDN18.2-expressing tumor cells; CD3+ T cells are engaged as effectors, not targeted for lysis.
A humanized IgG1 antibody-drug conjugate that targets B7-H3 (CD276). It is given intravenously every 3 weeks; upon binding B7-H3 on tumor cells it is internalized and releases a cytotoxic payload, and its IgG1 Fc may mediate ADCC/ADCP.
Humanized IgG1 ADC targeting B7-H3 (CD276); after binding B7-H3 on tumor cells it is internalized and releases a topoisomerase inhibitor payload that inhibits DNA topoisomerase activity, leading to replication arrest and apoptosis. The IgG1 Fc may also induce ADCC/ADCP.
YES
DIRECT
HS-20093 binds B7-H3 on target cells, is internalized, and releases a topoisomerase inhibitor payload that blocks DNA replication and induces apoptosis; its IgG1 Fc can also trigger ADCC/ADCP against B7-H3–positive cells.
A humanized IgG1 antibody-drug conjugate that targets B7-H3 (CD276). It is given intravenously every 3 weeks; upon binding B7-H3 on tumor cells it is internalized and releases a cytotoxic payload, and its IgG1 Fc may mediate ADCC/ADCP.
Humanized IgG1 ADC targeting B7-H3 (CD276); after binding B7-H3 on tumor cells it is internalized and releases a topoisomerase inhibitor payload that inhibits DNA topoisomerase activity, leading to replication arrest and apoptosis. The IgG1 Fc may also induce ADCC/ADCP.
NO
INDIRECT
The ADC binds B7-H3 on tumor cells, is internalized, and releases a topoisomerase inhibitor that blocks DNA topoisomerase, causing replication arrest and apoptosis; Fc may also trigger ADCC/ADCP. DNA topoisomerase itself is not the targeting determinant.
Hypoimmune allogeneic CD19-directed CAR T-cell therapy; genetically engineered T cells designed to evade host immune recognition and kill CD19+ B-cell malignancies.
Allogeneic T cells engineered to express an anti-CD19 chimeric antigen receptor bind CD19 on malignant B cells, triggering T-cell activation and cytotoxic killing. Hypoimmune edits—disruption of MHC class I/II and expression of CD47—reduce host immune recognition and rejection, increasing persistence and efficacy as an off-the-shelf product.
YES
DIRECT
Anti-CD19 CAR T cells bind CD19 on target cells, become activated, and kill via T-cell cytotoxic pathways (perforin/granzyme release and death receptor signaling).
Hypoimmune allogeneic CD19-directed CAR T-cell therapy; genetically engineered T cells designed to evade host immune recognition and kill CD19+ B-cell malignancies.
Allogeneic T cells engineered to express an anti-CD19 chimeric antigen receptor bind CD19 on malignant B cells, triggering T-cell activation and cytotoxic killing. Hypoimmune edits—disruption of MHC class I/II and expression of CD47—reduce host immune recognition and rejection, increasing persistence and efficacy as an off-the-shelf product.
NO
INDIRECT
SC291 CAR T cells target CD19, not SIRPα; they kill CD19+ cells via T-cell–mediated cytolysis (perforin/granzyme). CD47 on the CAR T cells engages SIRPα on myeloid cells to inhibit phagocytosis, so SIRPα+ cells are not targeted for killing.